Sports accounted for 96 of the 100 most-watched U.S. television broadcasts in 2025, and pharmaceutical companies have responded by embedding themselves inside professional leagues rather than merely buying commercial breaks. Novartis now runs cancer screening messages across national NFL broadcasts and local stadium activations spanning six NFL franchises. AbbVie has become Major League Baseball's first official pharmaceutical partner and has extended brain health awareness campaigns to the PGA Tour.

The shift marks a break from decades of convention. For most of the industry's history, pharmaceutical companies approached sporting events only through television advertising during commercial breaks, according to Ed Mitzen, founder of Fingerpaint Group and The Business For Good Foundation, writing in an analysis of the trend. Companies now want to reach fans by becoming part of the sporting experience itself, building relationships with leagues, athletes and audiences in ways that would have been unusual a decade ago.

Why is sports suddenly the priority channel?

The audience numbers explain the strategy. NFL games averaged 18.8 million viewers through the first five weeks of the 2026 season, the highest average at that point in a season on record, according to Sports Media Watch data cited in the analysis. At a time when audiences fragment across platforms, a captive audience of that scale has become rare, which is why brands are working to establish a permanent presence in professional sports.

Structural forces are also pushing the industry toward these deals. Healthcare digital advertising spending continues to grow and, as MIT Media Network reporting noted, has overtaken linear TV. At the same time, the FDA has launched a crackdown on deceptive drug advertising, prompting companies to reassess how they invest advertising dollars.

Two additional dynamics shape the opportunity. The growth of women's sports has opened new sponsorship territory, and greater openness among athletes about their mental and physical health has created conversations that extend well beyond competition.

Where does the strategy go wrong?

Mitzen identifies a familiar failure pattern. Pharmaceutical companies, he argued, are approaching sports partnerships with the same thinking that shaped traditional advertising: securing the audience first, then figuring out what to say.

The sequence matters, he wrote. A company signs a recognizable athlete, negotiates league sponsorship rights or invests in a high-profile activation. Only then does it ask how the arrangement supports broader business objectives. By that point, the investment has been made, and the pressure to justify it can become more important than determining whether it was the right decision.

Drawing on a career in healthcare marketing, Mitzen said he has seen how easily a promising partnership becomes an exercise in visibility rather than a strategy grounded in patients' needs.

What does authenticity require in healthcare?

Sports organizations and athletes hold a reliable position with communities that healthcare companies often struggle to reach through conventional advertising. These partnerships give companies a channel to address health topics patients are reluctant to discuss, using fan loyalty and athlete credibility.

Healthcare, however, demands more from spokespeople than typical consumer product endorsements. These campaigns often involve a sensitive diagnosis or a personal medical decision, requiring authenticity and vulnerability that standard advertising tactics cannot manufacture. Mitzen's test is direct: an athlete's genuine experience with a health issue is far more likely to resonate than a recognizable name attached to a generic message.

Without a clear understanding of the healthcare challenges a company is trying to address, these partnerships risk becoming just another advertising opportunity rather than a campaign built around intended outcomes.

How should success be measured?

The advertising industry, Mitzen argued, needs different metrics. Standard measures such as impressions, media coverage, brand awareness and social engagement quantify reach but reveal little about whether a campaign influenced health-related decisions. A partnership should not be assumed to have improved access to care or prompted patient action simply because those numbers are large.

Companies should define assessment criteria before investing: whether audiences sought additional information, discussed screening with a healthcare professional, or took steps toward scheduling an appointment. Not every outcome can be directly attributed to a sponsorship, but establishing objectives in advance provides a more substantial basis for evaluation.

The industry has already proven it can buy its way onto the biggest stages in professional sports. Whether it can convert that visibility into value for patients, Mitzen concluded, will determine whether these partnerships become a lasting part of healthcare marketing or simply another expensive way to compete for attention.